COST-MINIMIZATION ANALYSIS OF DAPTOMYCIN FOR MRSA SKIN AND SOFT TISSUES INFECTIONS IN BRAZILIAN PRIVATE SECTOR

Bueno RLP1, Prismic G2, Suzuki C1

1Fei, São Paulo, Brazil, 2Novartis Biotecnologias S/A, São Paulo, Brazil

OBJECTIVES: To analyze the cost-minimization of Daptomycin in comparison to Vancomycin and Linezolid for patients with Methicillin Resistant Staphylococcus Aureus (MRSA) skin and soft tissues infections in Brazilian private payer perspective.

METHODS: The alternatives were indirectly compared due to the absence of Head to Head studies. Resource consumption for MRSA treatment were collected from previous publication and divided into two categories: hospital care (including diagnostic tests) and pharmaceuticals. Total treatment cost was investigated for a base case where patients were treated in the best profile for each medicine effectiveness based on values extracted from randomized open or blind studies [Daptomycin: Length of stay (LOS) = 4 days with intravenous drug. Vancomycin: LOS = 7 days with intravenous drug. Linezolid: LOS = 4 days with intravenous drug and 11 days with oral drug]. The costs data regarding medicines were collected from companies price list or price submission process and utilization costs from literature. Results were converted in US Dollars (R$ 1.7/USD 1.00). A one-way sensitivity analysis was performed.

RESULTS: For base case the total treatment cost was US$1,664.89 for Daptomycin, US$1,843.84 for Vancomycin and US$3,290.46 for Linezolid. Pharmaceutical inpatient cost was US$129.93 higher for Daptomycin in comparison to Linezolid and US$868.31 higher when compared with generic-vancomycin; however this cost was offset by shorter LOS. Despite the unitary prices of the Vancomycin and Linezolid are lower than the price of Daptomycin, the total treatment costs with Linezolid and generic-vancomycin is higher than with Daptomycin. The sensitivity analysis on costs variables in an interval of +/-20%, was robust with the base case.

CONCLUSIONS: The Daptomycin is a cost-saving alternative for MRSA skin and soft tissues infections compared to generic-vancomycin and linezolid in the perspective of Brazilian private payer.

COMPARISON OF GENERIC AND BRAND NAME ANTIBIOTIC USAGE IN TURKEY

Malhan S1, Okuz E2, Tulunay FC2

1Baskent University, Ankara, Turkey, 2Ankara University Medical School, Ankara, Turkey

OBJECTIVES: Irrational antibiotic usage is still common in Turkey and antibiotics are still the most commonly used drug in Turkey. Our aim in this study was to evaluate the effects of generic drug usage in inpatient clinics in Turkey, incompared to brand names.

METHODS: Data was collected from one university hospital, internal medicine inpatient service for 1 month. A total of 62 patients were treated with an antibiotic. The antibiotic’s name, dosage and the duration of use were recorded by the nurses. The price of the antibiotics were extracted from the Ministry of Health’s official price list. We compared the cost of the bio-equivalent and the cheapest generic drugs with the original drugs.

RESULTS: During the month, the cost of the antibiotics used at the internal medicine inpatient clinic was €1136, compared to the cheapest generics, which was €1013. In this clinic, €2,2 per patient more was paid for the brand name antibiotics each month. If the 1400–1600 patients being treated with antibiotic in this hospital per year are considered, an average of €3300/month or €39,600/year is being paid for brand name antibiotics.

CONCLUSION: Considering antibiotics are the most common used medication in Turkey (17% of total drug usage), it can easily be understood how the use of Brand Name drugs rather than Generics would lead to a vast economic burden. This shows the importance of promoting the use of generic antibiotics and the need for cost-minimization analysis.